



CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers

Date: March 16, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Information Disclosure Statement	First Named Inventor	Terrence J. Connolly
Address to: Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450	Application Number	10/731,582
	Filing Date	December 9, 2003
	Group Art Unit	to be assigned
	Examiner	to be assigned
	Attorney Docket No.	R0156B-REG
	Title	NOVEL ANHYDROUS CRYSTALLINE 1-[4(S)-AZIDO-2(S),3(R)-DIHYDROXY- 4-(HYDROXYMETHYL)-1(R)- CYCLOPENTYL]CYTOSINE HEMISULFATE AS USEFUL AS AN ANTIVIRAL AGENT

Sir:

Transmittal for Information Disclosure Statement

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.56, which may be material to the patentability of the subject patent application.

Attached are:

- Form 1449, "Information Disclosure Statement By Applicants"
- Copies of references B1-B2 and C1-C2.
- Return postcard

The Information Disclosure Statement is being submitted (a) within three months of the filing date, or (b) before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**

Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,




Brian L. Buckwalter

Reg. No. 46,585

Agent for Applicants

Roche Palo Alto LLC
Patent Law Dept. M/S A2-250
3431 Hillview Avenue
Palo Alto, CA 94304
Direct Phone (650) 855-6995

Date: March 16, 2004



INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) Page 1 of 1		ATTY. DOCKET NO. R0156B-REG		SERIAL NO. 10/731,582
		FIRST NAMED INVENTOR Terrence Joseph Connolly		
		FILING DATE December 9, 2003		ART UNIT not known

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
B1	WO	02/18404	A2	F. Hoffmann-La Roche AG	07-Mar-2002			
B2	WO	01/100415	A1	F. Hoffmann-La Roche AG	19-Dec-2002			

THER PRIORITY ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	MOFFATT, J.G., "Chemical Transformations of the Sugar Moiety of Nucleosides", Nucleoside Analogues, (R. T. Walker, E. De Clercq, & F. Eckstein, eds.), (1979), pp. 71-164, Plenum Press, New York. (see p. 144)	
	C2	MAAG, Hans, et al., "Synthesis and Anti-HIV Activity of 4'-Azido- and 4'-Methoxynucleosides," J. Med. Chem., 1992, pp. 1440-1451, 35(8), (Table I)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

I. *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.